NASDAQ:OCUL

Ocular Therapeutix - OCUL Stock Forecast, Price & News

$2.76

-0.04 (-1.43%)

(As of 12/8/2022 05:25 PM ET)

Add

Compare

Today's Range: $2.73
▼
$2.88
50-Day Range: $2.79
▼
$5.13
52-Week Range: $2.73
▼
$7.39

Volume: 409,316 shs
Average Volume: 672,593 shs
Market Capitalization: $212.55 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $14.50

Ocular Therapeutix MarketRank™ Forecast

Analyst Rating: Buy
3.33 Rating Score
Upside/Downside: 425.4% Upside
$14.50 Price Target
Short Interest: Healthy
3.80% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -2.01
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Acquiring Shares
$750,000 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.99) to ($0.97) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.49 out of 5 stars

Medical Sector

151st out of 1,022 stocks

Pharmaceutical Preparations Industry

57th out of 499 stocks

3.7

Analyst's Opinion

Consensus Rating
Ocular Therapeutix has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $14.50, Ocular Therapeutix has a forecasted upside of 425.4% from its current price of $2.76.
Amount of Analyst Coverage
Ocular Therapeutix has only been the subject of 2 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
3.80% of the outstanding shares of Ocular Therapeutix have been sold short.
Short Interest Ratio / Days to Cover
Ocular Therapeutix has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Ocular Therapeutix has recently decreased by 12.01%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Ocular Therapeutix does not currently pay a dividend.
Dividend Growth
Ocular Therapeutix does not have a long track record of dividend growth.

4.1

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Ocular Therapeutix has received a 57.83% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Ophthalmologicals (S01)" and "Clinical research services for physiological diseases " products. See details.
Environmental Sustainability
The Environmental Impact score for Ocular Therapeutix is -2.01.

1.1

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Ocular Therapeutix this week, compared to 1 article on an average week.
Search Interest
14 people have searched for OCUL on MarketBeat in the last 30 days. This is an increase of 367% compared to the previous 30 days.
MarketBeat Follows
5 people have added Ocular Therapeutix to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ocular Therapeutix insiders have bought more of their company's stock than they have sold. Specifically, they have bought $750,000.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 3.60% of the stock of Ocular Therapeutix is held by insiders.
Percentage Held by Institutions
57.61% of the stock of Ocular Therapeutix is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Ocular Therapeutix are expected to grow in the coming year, from ($0.99) to ($0.97) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Ocular Therapeutix is -2.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Ocular Therapeutix is -2.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Ocular Therapeutix has a P/B Ratio of 2.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Ocular Therapeutix (NASDAQ:OCUL) Stock

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Receive OCUL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ocular Therapeutix and its competitors with MarketBeat's FREE daily newsletter.

OCUL Stock News Headlines

December 2, 2022 | forbes.com

Ocular Therapeutix

November 15, 2022 | marketwatch.com

Ocular Drug Delivery Sales Market : Research Report Provides an In-Depth Insight of Trends 2022 To 2028

December 8, 2022 | Investing Trends (Ad)

Minerals for Green Revolution a Massive Investor Opportunity

Demand for critical minerals needed to power green energy is expected to soar up to 40 times. China controls up to 90% of the desperately-needed supply and could throw the U.S. back into the stone age if it bans exports. One company is in hot pursuit of domestic sources with potentially big discoveries on the horizon.

November 15, 2022 | marketwatch.com

Ocular Drug Delivery System Market New Innovations and Future Expansion 2022-2028

November 13, 2022 | finance.yahoo.com

These Analysts Just Made A Neat Downgrade To Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Forecasts

November 8, 2022 | seekingalpha.com

Ocular Therapeutix hits 52-week low after slashing revenue guidance

November 8, 2022 | finance.yahoo.com

Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates (Revised)

November 7, 2022 | seekingalpha.com

Ocular Therapeutix, Inc. (OCUL) Q3 2022 Earnings Call Transcript

December 8, 2022 | Investing Trends (Ad)

Minerals for Green Revolution a Massive Investor Opportunity

November 7, 2022 | finance.yahoo.com

Ocular Therapeutix™ Reports Third Quarter 2022 Financial Results and Business Update

November 7, 2022 | finance.yahoo.com

Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates

November 4, 2022 | msn.com

A Preview Of Ocular Therapeutix's Earnings

October 24, 2022 | finance.yahoo.com

Ocular Therapeutix™ To Report Third Quarter 2022 Financial Results

October 17, 2022 | finance.yahoo.com

Investors in Ocular Therapeutix (NASDAQ:OCUL) have unfortunately lost 63% over the last year

October 14, 2022 | nasdaq.com

Despite Lacking Profits Ocular Therapeutix (NASDAQ:OCUL) Seems To Be On Top Of Its Debt

September 30, 2022 | finance.yahoo.com

Ocular Therapeutix (OCUL) Soars 24.2%: Is Further Upside Left in the Stock?

September 28, 2022 | nz.finance.yahoo.com

Ocular (OCUL) Announces Positive Data on Wet AMD Candidate

September 27, 2022 | marketwatch.com

Ocular Therapeutix Shares Drop Into Negative Territory After Early Bump

September 27, 2022 | seekingalpha.com

Ocular stock rises as eye drug implant OTX-TKI shows promise in vision disorder in trial

September 27, 2022 | marketwatch.com

Ocular Therapeutix Sees Positive Trial Results for OTX-TKI Wet AMD Treatment

September 27, 2022 | markets.businessinsider.com

Ocular Therapeutix Reports Positive Interim Data From Phase 1 Trial Of OTX-TKI For Wet AMD

September 27, 2022 | finance.yahoo.com

Ocular Therapeutix™ Announces Interim 7-month Data from U.S. Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD

September 26, 2022 | finance.yahoo.com

Allergy Relieving Eye Drops Market to record USD 354.94 Mn incremental growth -- Driven by high prevalence and incidence of eye infections

September 22, 2022 | finance.yahoo.com

Ocular Therapeutix™ To Present Data at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting

August 31, 2022 | finance.yahoo.com

Outlook on the Anti-snoring Devices and Snoring Surgery Global Market to 2030 - Featuring Ocular Therapeutix, SomnoMed and Resmed Among Others

August 30, 2022 | seekingalpha.com

EyePoint Pharmaceuticals: Key Player In The Long-Acting Wet AMD Space

August 26, 2022 | nz.finance.yahoo.com

Conjunctivitis Market to Grow at a Healthy CAGR of 5.8% from 2022 to 2032 Owing to Growing Disease Prevalence Globally | Future Market Insights, Inc.

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive OCUL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ocular Therapeutix and its competitors with MarketBeat's FREE daily newsletter.

OCUL Company Calendar

Last Earnings: 11/08/2021
Today: 12/08/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 2/27/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:OCUL
CUSIP: N/A
CIK: 1393434
Web: www.ocutx.com
Phone: (781) 357-4000
Fax: 781-357-4001
Employees: 228
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $14.50
High Stock Price Forecast: $25.00
Low Stock Price Forecast: $9.00
Forecasted Upside/Downside: +425.4%
Consensus Rating: Buy
Rating Score (0-4): 3.33
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.01)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-6,550,000.00
Net Margins: -119.35%
Pretax Margin: -119.35%
Return on Equity: -87.18%
Return on Assets: -33.69%

Debt

Debt-to-Equity Ratio: 1.15
Current Ratio: 4.98
Quick Ratio: 4.92

Sales & Book Value

Annual Sales: $43.52 million
Price / Sales: 4.88
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.15 per share
Price / Book: 2.40

Miscellaneous

Outstanding Shares: 77,010,000
Free Float: 74,238,000
Market Cap: $212.55 million
Optionable: Optionable
Beta: 1.35

Key Executives

Mr. Antony Mattessich (Age 55)
Pres, CEO & Director
Comp: $1.04M

Mr. Donald Notman Jr.
Chief Financial Officer

Dr. Peter K. Jarrett Ph.D. (Age 65)
Chief Scientific Officer

Mr. Philip C. Strassburger (Age 62)
Gen. Counsel

Mr. William H. Ransone II
VP of Global Sales & Marketing

Ms. Tracy Smith
VP of HR

Mr. Scott Corning
Sr. VP of Commercial

Mr. Christopher G. White (Age 60)
Chief Bus. Officer

Dr. Rabia Gurses Ozden M.D. (Age 54)
Chief Medical Officer

Dr. Karen-Leigh Edwards M.B.A.
Ph.D., Sr. VP of Technical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

OCUL Stock - Frequently Asked Questions

Should I buy or sell Ocular Therapeutix stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ocular Therapeutix in the last year. There are currently 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OCUL shares.
View OCUL analyst ratings or view top-rated stocks.
What is Ocular Therapeutix's stock price forecast for 2023?: 3 Wall Street research analysts have issued 12-month price objectives for Ocular Therapeutix's stock. Their OCUL share price forecasts range from $9.00 to $25.00. On average, they predict the company's share price to reach $14.50 in the next twelve months. This suggests a possible upside of 407.0% from the stock's current price.
View analysts price targets for OCUL or view top-rated stocks among Wall Street analysts.
How have OCUL shares performed in 2022?: Ocular Therapeutix's stock was trading at $6.97 at the start of the year. Since then, OCUL shares have decreased by 59.0% and is now trading at $2.86.
View the best growth stocks for 2022 here.
When is Ocular Therapeutix's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our OCUL earnings forecast.
How were Ocular Therapeutix's earnings last quarter?: Ocular Therapeutix, Inc. (NASDAQ:OCUL) announced its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping analysts' consensus estimates of ($0.26) by $0.03. The biopharmaceutical company had revenue of $12.15 million for the quarter, compared to analyst estimates of $12.13 million. Ocular Therapeutix had a negative net margin of 119.35% and a negative trailing twelve-month return on equity of 87.18%. During the same quarter in the prior year, the business earned ($0.17) EPS.
What other stocks do shareholders of Ocular Therapeutix own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Ocular Therapeutix investors own include Clearside Biomedical (CLSD), Northwest Biotherapeutics (NWBO), Novavax (NVAX), Dynavax Technologies (DVAX), Omeros (OMER), Gilead Sciences (GILD), TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO) and SCYNEXIS (SCYX).

What is Ocular Therapeutix's stock symbol?: Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL."
Who are Ocular Therapeutix's major shareholders?: Ocular Therapeutix's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.24%), Vanguard Group Inc. (5.13%), Deltec Asset Management LLC (3.02%), Emerald Advisers LLC (1.96%), State Street Corp (1.82%) and Emerald Mutual Fund Advisers Trust (1.41%). Insiders that own company stock include Antony C Mattessich, Opaleye Management Inc, Richard L Md Lindstrom and Summer Road Llc.
View institutional ownership trends.
How do I buy shares of Ocular Therapeutix?: Shares of OCUL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Ocular Therapeutix's stock price today?: One share of OCUL stock can currently be purchased for approximately $2.86.
How much money does Ocular Therapeutix make?: Ocular Therapeutix (NASDAQ:OCUL) has a market capitalization of $220.25 million and generates $43.52 million in revenue each year. The biopharmaceutical company earns $-6,550,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis.
How many employees does Ocular Therapeutix have?: The company employs 228 workers across the globe.
How can I contact Ocular Therapeutix?: Ocular Therapeutix's mailing address is 15 CROSBY DRIVE, BEDFORD MA, 01730. The official website for the company is www.ocutx.com. The biopharmaceutical company can be reached via phone at (781) 357-4000, via email at chris.brinzey@westwicke.com, or via fax at 781-357-4001.

This page (NASDAQ:OCUL) was last updated on 12/8/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial